Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Shares of Eli Lilly & Co. LLY slipped 1.88% to $906.18 Tuesday, on what proved to be an all-around mixed trading session for ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

We recently compiled a list of Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025. In this article, we are going to ...

Eli Lilly And Co’s Profitability and Valuation Ratios Eli Lilly And Co’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 34.50% and a profit ...

Eli Lilly (LLY ... has resulted in a Zacks Rank #3 (Hold) for Lilly. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: ...

Eli Lilly's weight loss drugs are bringing in billions of dollars in revenue, and their performance even prompted the company to increase its annual revenue guidance. But one thing has limited the ...

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co ... intensifying the company's race with ...

An Eli Lilly insulin engineered for once-weekly dosing now has preliminary results from two more pivotal studies showing the injection was comparable to once-daily insulin, a new slate of data ...